Norges Bank Invests $96.77 Million in Charles River Laboratories International, Inc. $CRL

Norges Bank purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 485,087 shares of the medical research company’s stock, valued at approximately $96,765,000.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after purchasing an additional 47,432 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after purchasing an additional 9,756 shares during the last quarter. Invesco Ltd. raised its stake in shares of Charles River Laboratories International by 1.0% during the third quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock worth $195,446,000 after purchasing an additional 12,035 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Charles River Laboratories International by 13.4% during the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after purchasing an additional 137,335 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Charles River Laboratories International by 11.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after purchasing an additional 120,207 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.3%

NYSE:CRL opened at $181.46 on Friday. The stock has a fifty day moving average price of $171.37 and a two-hundred day moving average price of $181.57. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of -48.26, a PEG ratio of 2.12 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $143.06 and a 1 year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CRL. Royal Bank Of Canada began coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Barclays increased their price objective on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price objective for the stock from $167.00 to $219.00 in a research report on Friday, May 29th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $208.50.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.